High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department

• Status: Recruiting
• Trial end date: 2022-04-14
• Target enrollment: 0
• Participant gender: All

Summary

Intravenous lidocaine will be given at a dose of 2 mg/kg intravenously to patients in the emergency department with a diagnosis of acute abdominal pain. Its efficacy will be compared to 1 mg of intravenous hydromorphone, with a primary endpoint of mean improvement of pain at 90 minutes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hennepin Healthcare Research Institute
• Treatments: Hydromorphone; Lidocaine

Criteria

Inclusion Criteria:

• Must be a patient in the emergency department (ED)

• Must have acute abdominal pain, defined as abdominal or flank pain of a duration of 7 days or less

• Predicted treatment must include the use of an intravenous opiate

Exclusion Criteria:

• Cardiac conduction system impairment (QTc duration > 0.5s, QRS duration > 0.12s, PR interval <0.12s or > 0.2s)

• Known renal (CKD >2) or liver disease (Childs-Pugh B or greater)

• Hemodynamically instability, defined by the attending physician

• Pregnant or breastfeeding

• Have a known allergy to either medication

• Used of prescription or illicit opioids within the previous week

• Patients with a chronic pain disorder, defined as use of any analgesic medication on more days than not during the four weeks preceding the acute episode of pain